Back to top
more

Rigel Pharmaceuticals (RIGL)

(Delayed Data from NSDQ)

$0.95 USD

0.95
1,044,112

-0.03 (-3.53%)

Updated May 14, 2024 04:00 PM ET

After-Market: $0.95 0.00 (0.26%) 5:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value A Growth F Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 37% (92 out of 250)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for RIGL

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

Rigel Pharmaceuticals, Inc. [RIGL]

Reports for Purchase

Showing records 21 - 40 ( 112 total )

Company: Rigel Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 21

06/08/2022

Company Report

Pages: 8

FORWARD Phase 3 Top-Line Falls Short a Step; Geographic Differences May Have Role; Target Reduced to $7

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Company: Rigel Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 22

05/04/2022

Company Report

Pages: 7

1Q22 Results; All Eyes on wAIHA Phase 3 Data Next Month; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Company: Rigel Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 23

03/02/2022

Company Report

Pages: 7

2021 Results; Expecting Big Push FORWARD Mid-Year; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Company: Rigel Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 24

01/10/2022

Company Report

Pages: 7

Tavalisse Progress Continues; Fruitful 2022 Expected Including Pivotal Readout for wAIHA; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Company: Rigel Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 25

12/21/2021

Daily Note

Pages: 5

Tavalisse Closer to Conquering Asia; Positive Initial Phase 3 Data for cITP in Japan

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 5.00

Research Provided by a Third Party

Company: Rigel Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 26

11/03/2021

Company Report

Pages: 7

3Q21 Results; FORWARD March to Data Now; ITP Sales Blocking and Tackling witth Improving Trends

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Company: Rigel Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 27

09/28/2021

Daily Note

Pages: 4

Tavlesse Reach Broadens in the E.U.

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 10.00

Research Provided by a Third Party

Company: Rigel Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 28

09/28/2021

Company Report

Pages: 10

ValuEngine Detailed Valuation Report for RIGL

Provider: ValuEngine, Inc

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: Rigel Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 29

08/13/2021

Daily Note

Pages: 4

Size Matters This Time, But FDA Still Strongly Engaged With Tavalisse COVID Thesi

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 10.00

Research Provided by a Third Party

Company: Rigel Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 30

08/06/2021

Daily Note

Pages: 4

Tavalisse''s Global Market Development Bears Fruit

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 10.00

Research Provided by a Third Party

Company: Rigel Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 31

08/04/2021

Company Report

Pages: 7

2Q21 Results; Tavalisse Sales Regain Solid Footing; Clinical Pipeline Poised to Cross Finish Line

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Rigel Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 32

06/29/2021

Daily Note

Pages: 6

Tavalisse One Step Closer to COVID-19 Patients with Selection for NIH ACTIV-4 Phase 3 Trial

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Rigel Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 33

06/03/2021

Company Report

Pages: 7

Tavalisse On Its Way to Reach COVID-19 Patients; EUA Filed With the FDA

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Rigel Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 34

05/06/2021

Company Report

Pages: 8

1Q21 Results; Tavalisse Sales Hit a Snag Due To COVID-19, But Clinical Programs Show Strong Signs for Bouncing Back

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Rigel Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 35

04/13/2021

Company Report

Pages: 7

Tavalisse Cuts SAEs in Half in Severe COVID Patients and Improves Clinical Outcomes

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Rigel Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 36

03/11/2021

Daily Note

Pages: 5

Tavalisse Wraps Up Enrollment in Phase 2 COVID-19 Study; Results Expected Next Month

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 10.00

Research Provided by a Third Party

Company: Rigel Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 37

03/03/2021

Company Report

Pages: 7

2020 Results; Tavalisse Traction Continues; COVID-19 Program Updates Ahead

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Rigel Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 38

02/18/2021

Company Report

Pages: 6

Lilly Steps Up Big for RIPK1; Rigel Can Play Nice Role If It Wants; Target Increased to $11

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Rigel Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 39

01/11/2021

Company Report

Pages: 7

Tavalisse Continues Positive Push Forward as Rigel Remains Quite Busy

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Rigel Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 40

11/06/2020

Company Report

Pages: 6

3Q20 Results; Commercial Blocking and Tackling Working in the Face of COVID-19

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party